Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
Matt Weinstock(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Gavin Thurston(Regeneron (United States)), Srikanth Ambati(Regeneron (United States)), Robin Joyce(Beth Israel Deaconess Medical Center), Stephane Pourpe(Regeneron (United States)), Raquel P. Deering(Regeneron (United States)), Nathalie Fiaschi(Regeneron (United States)), Pavania Elavalakanar(Beth Israel Deaconess Medical Center), Vladimir Janković(Regeneron (United States)), Jurriaan Brouwer‐Visser(Montefiore Medical Center), Aafia Chaudhry(Regeneron (United States)), Susan Bright(Center for Veterinary Medicine)
Cited by 7
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k